Product/Composition:- | Olmesartan tablets |
---|---|
Strength:- | 5 mg, 20 mg, 40 mg |
Form:- | Tablets |
Reference Brands:- | Benicar(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Olmesartan is an angiotensin II receptor blocker (ARB) that prevents blood vessels from constricting by blocking angiotensin II effects. It effectively lowers blood pressure, reduces stroke and heart attack risk, and supports cardiovascular health. Benefits include improved blood pressure control, decreased cardiovascular events, and enhanced long-term heart and kidney protection.
Olmesartan tablets, marketed as Benicar, are approved in the US by the FDA and in the EU via EMA for hypertension and cardiovascular risk reduction. Regulatory approval requires a detailed dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews comprehensive clinical trial and quality data, while the EMA ensures compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence to regional regulations supports timely approval, safe use, and global availability, helping manage hypertension effectively and improve cardiovascular health worldwide.